English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Levkovich N.M., Gorovenko N.H., Sheiko M.V.

    COMMUNICATION OF POLYMORPHIC VARIANT C3435T OF MULTIDRUG RESISTANCE GENE TYPE 1 (MDR1) WITH DEVELOPMENT OF AFFECTIVE DISORDERS


    About the author: Levkovich N.M., Gorovenko N.H., Sheiko M.V.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation The results of determination of polymorphic variant C3435T of MDR1 gene in 144 patients with affective disorders (AD) and 103 healthy control people. A statistically significant difference between research groups for C3435T genotype [χ2=6,61, p=0,001, OR=0,51 (95% CI: 0,31-0,86)] and T3435T genotype [χ2=6,8, p=0,009, OR=2,22 (95% CI: 1,21-4,07)]. Was determined that the combination of C3435C and C3435T genotypes had protective value in in developing of AD [χ2=6,8, p=0,009, OR=0,45 (95% CI: 0,25-0,83)], while a presence of T3435T genotype increased risk of AD in 2 times with respect to control. As a result of our study, it was found an increased risk of AD compared with the control group for T3435T genotype of MDR1 gene.
    Tags gene, polymorphism, affective disorders
    Bibliography
    • Абрамов В.А. Социально-демографические особенности больных с первым депрессивным эпизодом / В.А. Абрамов, А.И. Жислин //  – 2008. – №3 (20). – С.10-15.
    • Вартанян М.Е. Современные проблемы генетики психиатрических заболеваний / М.Е. Вартанян // Проблемы медицинской генетики: сб. ст. – М., 1970. – С.495-509.
    • Марута Н.О. Стан психічного здоров’я населення та психіатричної допомоги в Україні / Н.О. Марута // НейроNews. – 2010. – № 5 (24). – С.83-90.
    • Полищук И.А. Шизофрения. / И.А.  Полищук //- Киев: Здоровье, 1976., 262 с.
    • Ben-Yehuda D. Therapy-related leukemia: сlinical characterstics and analysis of new molecular risk factors in 96 patients / D. Ben-Yehuda, S. Krichevsky, S. Shafran [et al.] // Blood. – 2002. – Vol.100. – 324 р.
    • Drozdzik M. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease / M. Drozdzik, M. Bialecka, K. Mysliwiec [et al.] // Pharmacogenetics. – 2003. – Vol.13, № 5. – P.259-263.
    • Friedhoff A.J. Isolation and characterization of a compound from the urine of schizophrenics / A.J. Friedhoff, E. Van Winkle // Nature. – 1962. – Vol. 194. – Р.897-898.
    • Furuno T.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease / T. Furuno, M.T. Landi, M. Ceroni [et al.] // Pharmacogenetics. – 2002. – Vol.12. – P.529-534.
    • Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia / K. Jamroziak, W. Mlynarski, E. Balcerczak [et al.] // Eur. J. Haematol. – 2004. – Vol.72, № 5. – P.314-321.
    • Heath R.G. Schizophrenia as an immunologic disorder / R.G. Heath, I.M. Krupp, L.W. Byers, J.I. Liljekvist // Arch. Gen. Psychiatry. – 1967. – Vol.16, №1. – Р.24-33.
    • Hoffmeyer S. Functional polymorphisms of the human multidrug resistance gene: multiple bequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo / S. Hoffmeyer, O. Burk, O. von Richter [et al.] // Prnc. Nut1. Acud. Sci. USA. – 2000. – Vol. 97. –P.3473-3478.
    • Latham L.K.  Effect of a protein factor isolated from schizophrenic blood on permeability / L.K. Latham, K.Loncharich, K.A. Warner [et al.] // Vox Sanguinis. – 1963. – Vol.8, №4. – Р.491-496.
    • Miller D.S. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy / D.S. Miller, B. Bauer, A.M.S. Hartz // Pharmacol. Rev. – 2008. – Vol.60. – P.196-209.
    • Nurnberger J.I. Jr. A simulated genetic structure for bipolar illness / J.I. Jr. Nurnberger // – 2008. – Vol. 147 (B). – P.952-956.
    Publication of the article «World of Medicine and Biology» №3(39) 1 part 2013 year, 120-123 pages, index UDK 575.191:616.89-008:615.015.5